Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guanabenz in early childhood onset vanishing white matter (extension study)
2024-518834-95-02Phase 2Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of guanabenz in leukoencephalopathy with vanishing white matter (VWM), sponsored by Amsterdam University Medical Center. Primary endpoint: Ambulation change from VWM1 baseline to end of VWM2. Planned start Nov 2025; status: authorised.
02
Drugs
guanabenz
03
Conditions
leukoencephalopathy with vanishing white matter (VWM)
Beyond the preview
Go deeper on 2024-518834-95-02.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518834-95-02.